Results 11 to 20 of about 27,891 (313)

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes [PDF]

New England Journal of Medicine, 2016
Background: Regulatory guidance specifies the need to establish cardiovascular safety of new diabetes therapies in patients with type 2 diabetes in order to rule out excess cardiovascular risk.
Bain, Stephen C., Baldassarre, Maria Pompea Antonia, Consoli, Agostino, Eliaschewitz, Freddy G., Hansen, Oluf, Holst, Anders G., Jodar, Esteban, Leiter, Lawrence A., Lingvay, Ildiko, Marso, Steven P, Pettersson, Jonas, Rosenstock, Julio, Seufert, Jochen, Vilsboll, Tina, Warren, Mark L., Woo, Vincent   +15 more
core   +3 more sources

Once-Weekly Semaglutide in Adults with Overweight or Obesity.

New England Journal of Medicine, 2021
BACKGROUND Obesity is a global health challenge with few pharmacologic options. Whether adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 mg as an adjunct to lifestyle intervention has not been confirmed ...
J. Wilding, R. Batterham, S. Calanna, M. Davies, L. V. Van Gaal, I. Lingvay, B. McGowan, J. Rosenstock, Marie T D Tran, T. Wadden, S. Wharton, K. Yokote, N. Zeuthen, R. Kushner   +13 more
semanticscholar   +1 more source

The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis

Contemporary Clinical Trials Communications, 2022
Aim: Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) indicated for glycaemic management in adults with type 2 diabetes (T2D).
Yousef Alhindi, Amanda Avery
doaj   +1 more source

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.

New England Journal of Medicine, 2023
BACKGROUND Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in
A. M. Lincoff, K. Brown-Frandsen, H. Colhoun, J. Deanfield, S. Emerson, Sille Esbjerg, S. Hardt-Lindberg, G. Hovingh, S. Kahn, Robert F. Kushner, I. Lingvay, Tugce K Oral, Marie M Michelsen, Jorge Plutzky, C. W. Tornøe, D. Ryan   +15 more
semanticscholar   +1 more source

Semaglutide and pregnancy

International Journal of Gynecology & Obstetrics, 2023
SynopsisBoth use and cessation of semaglutide constitutes problems prior to and during pregnancy. More problems are expected with increasing use.
Kenneth Skov, Ida Nikoline Mandic, Kathinka Marie Nyborg   +2 more
openaire   +3 more sources

Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China

Frontiers in Pharmacology, 2021
Introduction: Semaglutide is the first and only oral version of a glucagon-like peptide-1 analogue approved by the FDA for the treatment of type 2 diabetes (T2D). This research was designed to explore the appropriate price of once-weekly (OW) semaglutide
Shanshan Hu, Shanshan Hu, Xiaorong Su, Xun Deng, Xun Deng, Yong Wang, Yong Wang   +6 more
doaj   +1 more source

Semaglutide reduces alcohol intake and relapse-like drinking in male and female ratsResearch in context

EBioMedicine, 2023
Summary: Background: Glucagon-like peptide1 receptor (GLP-1R) agonists have been found to reduce alcohol drinking in rodents and overweight patients with alcohol use disorder (AUD).
Cajsa Aranäs, Christian E. Edvardsson, Olesya T. Shevchouk, Qian Zhang, Sarah Witley, Sebastian Blid Sköldheden, Lindsay Zentveld, Daniel Vallöf, Maximilian Tufvesson-Alm, Elisabet Jerlhag   +9 more
doaj   +1 more source

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes:a substudy of the SUSTAIN 8 randomised, controlled clinical trial [PDF]

, 2020
Aims/hypothesis: Intra-abdominal or visceral obesity is associated with insulin resistance and an increased risk for cardiovascular disease. This study aimed to compare the effects of semaglutide 1.0 mg and canagliflozin 300 mg on body composition in a ...
Catarig, Andrei-Mircea, Frias, Juan P., Lausvig, Nanna L., le Roux, Carel W., Lingvay, Ildiko, McCrimmon, Rory, Thielke, Desirée   +6 more
core   +2 more sources

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.

New England Journal of Medicine, 2023
BACKGROUND Heart failure with preserved ejection fraction is increasing in prevalence and is associated with a high symptom burden and functional impairment, especially in persons with obesity.
M. Kosiborod, S. Z. Abildstrom, B. Borlaug, J. Butler, S. Rasmussen, M. Davies, G. Hovingh, D. Kitzman, M. Lindegaard, D. Møller, Sanjiv J. Shah, M. Treppendahl, S. Verma, W. Abhayaratna, F. Ahmed, V. Chopra, J. Ezekowitz, Michael Fu, Hiroshi Ito, M. Lelonek, V. Melenovský, B. Merkely, Julio Núñez, E. Perna, M. Schou, M. Senni, K. Sharma, P. van der Meer, Dirk von Lewinski, Dennis Wolf, M. Petrie   +30 more
semanticscholar   +1 more source

Population pharmacokinetic of paracetamol and atorvastatin with co‐administration of semaglutide

Pharmacology Research & Perspectives, 2022
Semaglutide is a glucagon‐like‐peptide‐1 (GLP‐1) analogue marketed for once‐weekly subcutaneous administration for type 2 diabetes mellitus. Like other long‐acting GLP‐1 analogues, semaglutide reduces gastric emptying and, potentially, alters the rate of
Emilie K. Langeskov, Kim Kristensen
doaj   +1 more source